Loading
The classic first treatment for acute myeloid leukaemia, unchanged since 1973: seven days of continuous cytarabine plus three days of an anthracycline, given in hospital. Fit patients still get it, now with a targeted drug added according to their leukaemia's genetics.
7+3 achieves complete remission in 60-80% of younger adults and is followed by consolidation (high-dose cytarabine) or allogeneic transplant depending on ELN risk. Additions by genotype: midostaurin or quizartinib for FLT3 mutations, gemtuzumab ozogamicin for favourable-risk CD33-positive disease, CPX-351 (liposomal 7+3) for secondary AML. Patients unfit for intensive chemotherapy receive venetoclax plus azacitidine, which is eroding the boundary between 'intensive' and 'non-intensive' approaches. Induction mortality is 5-10% and the main risks are infection and bleeding during weeks of aplasia.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Showing the molecule this term concerns: Venetoclax.
Shares Midostaurin, Gilteritinib, FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares Gilteritinib, Azacitidine, Venetoclax, Acute myeloid leukaemia.
Shares Midostaurin, Gilteritinib, FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares Gilteritinib, FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares Midostaurin, Gilteritinib, FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares Midostaurin, Gilteritinib, FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares Gilteritinib, FLT3-mutated acute myeloid leukaemia, Acute myeloid leukaemia.
Shares Gilteritinib, Azacitidine, Venetoclax.